EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structural insights into allosteric inhibition of HRI kinase by heme binding via HDX-MS

Shivani Kanta, Vanesa Vinciauskaite iD, Graham Neill iD, Miratul M K Muqit iD, Glenn R Masson iD

Biochemical Journal · 2025

DOI: 10.1042/bcj20253072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Journal, 2025. Verfasst von Shivani Kanta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Research, School of Medicine, University of Dundee, Dundee DD1 9SY, U.K. Hauptthemen laut MEDLINE: Heme, Protein Kinase Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Royal Society, Biotechnology and Biological Sciences Research Council, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heme-regulated inhibitor (HRI) is one of the four mammalian kinases that phosphorylate eIF2α, facilitating a cellular response to stress through the regulation of mRNA translation. Originally identified as a heme sensor in erythroid progenitor cells, HRI has since emerged as a potential therapeutic target in both cancer and neurodegeneration. Here, we characterise two modes of HRI inhibition using structural mass spectrometry, biochemistry, and biophysics. We examined several competitive ATP-mimetic inhibitors – dabrafenib, encorafenib, and GCN2iB – and compared them with the heme-mimetic allosteric inhibitor, hemin. By combining hydrogen–deuterium exchange mass spectrometry with protein models generated by AlphaFold 3, we investigated the structural basis of inhibition by dabrafenib and hemin. Our analysis revealed that hemin inhibition induces large-scale structural rearrangements in HRI, which are not observed with ATP-mimetic inhibitors. Our results suggest that HRI may be inhibited using two distinctly different modalities, which may guide future drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemeProtein Kinase InhibitorsAllosteric RegulationHumansHydrogen Deuterium Exchange-Mass SpectrometryHeminOximesImidazolesProtein Binding

Stichwörter der Autor:innen

hydrogen–deuterium exchange mass spectrometryironprotein-serine-threonine kinasesprotein-tyrosine kinasesstress kinasesstress response

Substanzen

HemeProtein Kinase InhibitorsHemindabrafenibOximesImidazoles

Autor:innen und Institutionen

  • Division of Cancer Research, School of Medicine, University of Dundee, Dundee DD1 9SY, U.K.
  • MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.

ORCID-Profile: Vanesa Vinciauskaite, Graham Neill, Miratul M K Muqit, Glenn R Masson

Förderung

  • The Royal Society
  • Biotechnology and Biological Sciences Research Council
  • Medical Research Council

Zitieren

APA

Kanta, S., Vinciauskaite, V., Neill, G., Muqit, M. M. K., & Masson, G. R. (2025). Structural insights into allosteric inhibition of HRI kinase by heme binding via HDX-MS. Biochemical Journal. https://doi.org/10.1042/bcj20253072

Vancouver

Kanta S, Vinciauskaite V, Neill G, Muqit MMK, Masson GR. Structural insights into allosteric inhibition of HRI kinase by heme binding via HDX-MS. Biochemical Journal. 2025. doi:10.1042/bcj20253072

BibTeX
@article{Kanta2025,
  author = {Kanta, Shivani and Vinciauskaite, Vanesa and Neill, Graham and Muqit, Miratul M K and Masson, Glenn R},
  title = {Structural insights into allosteric inhibition of HRI kinase by heme binding via HDX-MS},
  journal = {Biochemical Journal},
  year = {2025},
  doi = {10.1042/bcj20253072}
}
Kostenlos starten →